X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    development of new antibiotics

    EMA guidance supports development of new antibiotics

    Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows

    Commercial Success In New Biopharmaceutical Innovation Era

    Proteros and AstraZeneca Boost Collaboration Agreement

    Conver to wp

    AbbVie and Cugene Join Forces Concerning Autoimmune Disorders and Cancer

    Drug Imagent For Therapeutic Platform

    Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

    Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities

    Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

    AstraZeneca announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD meets primary efficacy endpoint

    AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts

    Lynparza approved in the EU for BRCA-mutated metastatic pancreatic cancer

    Major Success Factors For Clinical Development Organizations

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    development of new antibiotics

    EMA guidance supports development of new antibiotics

    Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows

    Commercial Success In New Biopharmaceutical Innovation Era

    Proteros and AstraZeneca Boost Collaboration Agreement

    Conver to wp

    AbbVie and Cugene Join Forces Concerning Autoimmune Disorders and Cancer

    Drug Imagent For Therapeutic Platform

    Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

    Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities

    Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

    AstraZeneca announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD meets primary efficacy endpoint

    AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts

    Lynparza approved in the EU for BRCA-mutated metastatic pancreatic cancer

    Major Success Factors For Clinical Development Organizations

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development Research & Development

Allergan Launches See America , a Bold Initiative Furthering the Fight Against Preventable Blindness

Yuvraj_pawp by Yuvraj_pawp
7th February 2017
in Research & Development

Allergan plc , a global leader in eye care for nearly 70 years, announces a bold commitment to fight preventable blindness in the United States with a new initiative See America.

Through See America, Allergan sets out to make vision health a priority for all Americans, increase awareness of the diseases that can cause preventable blindness and, critically, help improve access to vision care for those who need it most.


The launch follows the release of a major report published in September 2016 by the National Academies of Sciences, Engineering, and Medicine (NASEM), declaring eye health a public health imperative. The report recognized the overwhelming number of Americans affected by blindness from preventable causes. Therefore, NASEM put forth a nationwide rallying cry, encouraging all of America to prioritize proactive eye care.


“Vision loss from diseases such as glaucoma and diabetic retinopathy is affecting and destroying the lives of too many—with cases of preventable blindness increasing at such a frightening rate,” said Herm Cukier, Senior Vice President, Eye Care. “We are launching See America to stress the importance of eye health. The time to act is now.”


Without a nationwide intervention, cases of preventable blindness and visual impairment are projected to double by 20501. At this rate, one American will experience partial or complete loss of sight every four minutes2– costing the U.S. economy trillions of dollars3 over the next thirty-four years.


Through See America, Allergan will partner with the nation’s leading volunteer eye health and safety organization, Prevent Blindness, to champion better access to vision care. Through a series of vision-screening events in various cities, sponsored by Allergan, attendees will receive free one-on-one professional eye exams, follow-up treatment plans and education about the most common diseases affecting people’s vision. In addition to sponsoring Prevent Blindness, Allergan will look to partner on programs from like-minded organizations that support the goals of See America.


Many people are not aware of the perils associated with neglecting their vision. Currently, 61 million Americans are at risk of severe vision loss more than the populations of California and Florida combined4. Yet, only half of those at risk visited an eye doctor in the last year5.


Board Certified Ophthalmologist, Dr. Elizabeth Yeu, believes the key to effective treatment is early detection. “As an ophthalmologist, I’ve seen the endless ways in which vision loss burdens my patients’ lives,” states Yeu. “In certain cases, their vision loss could have been prevented if they had sought out treatment sooner. I’m so happy to be a part of this initiative to shine a spotlight on the problem and rally the support we need to affect change.”6

With an unrivaled eye care portfolio, a national network of medical experts and an unwavering commitment to the future of America’s eyesight, Allergan is standing at the forefront to answer NASEM’s call. For Allergan, this is only the beginning but the message is clear – to fight until the fight has been won.

To learn more about See America and prioritize your own vision, visit www.SeeAmerica.vision.

ABOUT ALLERGAN PLC.

Allergan plc , headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model Growth Pharma. Allergan is focused on developing, manufacturing and commercializing branded pharmaceuticals, devices and biologic products for patients around the world.

Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women’s health, urology and anti-infective therapeutic categories.


Allergan is an industry leader in Open Science, the Company’s R&D model, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. This approach has led to Allergan building one of the broadest development pipelines in the pharmaceutical industry with 70+ mid-to-late stage pipeline programs in development.


Our Company’s success is powered by our more than 16,000 global colleagues’ commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.


With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.
For more information, visit Allergan’s website at www.Allergan.com

 

CONTACTS:

Media:
Mark Marmur
mark.marmur@allergan.com

+1 (862) 261 7558

Suzanne Jacobson
suzanne.jacobson@allergan.com

+1 (201) 427 8879


Lisa DeFrancesco

investorrelations@allergan.com

+1 (862) 261 7152

Previous Post

Arven Pharma selects GE Healthcare to improve Turkish and regional access to biopharmaceuticals

Next Post

Jazz Pharm announces first patient enrolled in phase 2 clinical study evaluating JZP-110

Related Posts

Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows
Manufacturing

Commercial Success In New Biopharmaceutical Innovation Era

21st May 2022
Manufacturing

Proteros and AstraZeneca Boost Collaboration Agreement

18th May 2022
SEQENS Makes Multi-Million-Dollar Investment in U.S. R&D Laboratory
Middle East and South Asia

SEQENS Makes Multi-Million-Dollar Investment in U.S. R&D Laboratory

22nd March 2022
Exscientia and Sanofi establish strategic research collaboration to develop AI-driven pipeline of precision-engineered medicines
Press Statements

Exscientia and Sanofi establish strategic research collaboration to develop AI-driven pipeline of precision-engineered medicines

17th January 2022
COVID-19 Impact On Changing Pharma Research And Development
News

COVID-19 Impact On Changing Pharma Research And Development

12th January 2022
immuno-oncology therapies
Drug Development

AbbVie, University of Chicago Extend Research Collaboration to Support Preclinical Oncology Research Through 2025

19th November 2021
Next Post

Jazz Pharm announces first patient enrolled in phase 2 clinical study evaluating JZP-110

Latest News

Dupixent From Sanofi Delivers Another Fantastic Performance
Manufacturing

Sanofi Sets Up Fund To Enable Firms In Low-Income Countries

5th July 2022
GSK commences phase III study of Benlysta and rituximab combination in systemic lupus erythematosus
Manufacturing

Singapore Authorises New Ovarian Cancer Treatment By GSK

5th July 2022
Abbott Is Named Global Industry Leader in Sustainability for the Sixth Consecutive Year on the Dow Jones Sustainability Index (DJSI)
Manufacturing

Abbott India Affirms That The Medicines Are Not Their Own

5th July 2022
Global Biopharmaceutical Bioseparation Market Eyeing $20bn
Manufacturing

Global Biopharmaceutical Bioseparation Market Eyeing $20bn

4th July 2022
FDA Advises Adding Omicron BA.4, 5 To COVID-19 Boosters
Manufacturing

FDA Advises Adding Omicron BA.4, 5 To COVID-19 Boosters

4th July 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In